Free tool
FAERS Monitor: Cysview Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022555 or its brand name (Cysview Kit, Hexaminolevulinate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
44
Serious
9
20% of reports
Hospitalization
2
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9
- medication error4
- pain4
- anaphylactic shock3
- burning sensation3
- hypersensitivity3
- micturition urgency3
- accidental exposure to product2
- cardiac arrest2
- cardio-respiratory arrest2
- hyperhidrosis2
- hypotension2
- no adverse event2
- occupational exposure to product2
- tachycardia2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,115 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| occupational exposure to product | 2 | 148.8 | 38.4 | 164 |
| micturition urgencySignal | 3 | 125.6 | 42.1 | 257 |
| anaphylactic shockSignal | 3 | 55.6 | 18.7 | 111 |
| medication errorSignal | 4 | 34.4 | 13.5 | 99 |
| cardio-respiratory arrest | 2 | 22.9 | 5.9 | 23 |
| burning sensationSignal | 3 | 20.5 | 6.9 | 38 |
| cardiac arrest | 2 | 11.6 | 3.0 | 10 |
| tachycardia | 2 | 10.8 | 2.8 | 9 |
| accidental exposure to product | 2 | 9.3 | 2.4 | 8 |
| hypersensitivitySignal | 3 | 7.7 | 2.6 | 12 |
| hyperhidrosis | 2 | 7.4 | 1.9 | 6 |
| no adverse event | 2 | 5.3 | 1.4 | 3 |
| hypotension | 2 | 4.8 | 1.2 | 3 |
| drug ineffectiveSignal | 9 | 3.3 | 1.8 | 13 |
| pain | 4 | 3.1 | 1.2 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.